Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEVI-007 · 1 trial · 1 indication
Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.
| Arm | Type | Description |
|---|---|---|
| AEVI-007 | EXPERIMENTAL | Open-label, dose-escalation, single-arm |
| Name | Type | Description |
|---|---|---|
| AEVI-007 | DRUG | 50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection. |
Inclusion Criteria: 1. Subject has active R/R multiple myeloma. 2. Subject has measurable myeloma based on any of the following: * Serum M-protein \> 0.5 g/dL * Urine M-protein \> 200 mg/24 hours * Serum free light chains \> 10 mg/dL * Measurable plasmacytoma or extramedullary disease ...
Top 20 of 25 competitors
AEVI-007 is an investigational small molecule being developed for the treatment of multiple myeloma, a type of blood cancer. It is being studied in patients with relapsed or refractory multiple myeloma, meaning the disease has returned or has not responded to prior treatment.
AEVI-007 is being developed by Avalo Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol AVTX. The company is conducting clinical research on this small molecule for the oncology indication of multiple myeloma.
AEVI-007 is in Phase 1 clinical development. A Phase 1b study of the drug in subjects with relapsed or refractory multiple myeloma has been completed. The drug is investigational and has not been approved by regulatory authorities.
AEVI-007 has been studied in a completed Phase 1b clinical trial with the identifier NCT04671251. The trial enrolled 13 participants with relapsed or refractory multiple myeloma in the United States. The study was uncontrolled and did not use randomization or blinding.
AEVI-007 is the drug name used in clinical development for this investigational small molecule. No alternative names have been established in the available clinical trial information, and it is identified solely as AEVI-007 in the completed Phase 1b study.